Triangle Pharmaceuticals (VIRS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Triangle Pharmaceuticals (VIRS)

VIRS 40.03

0.0%

Oct 10 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jack Hartmann who wrote (27)	3/4/2000 9:39:00 PM
From: Jack Hartmann	Read Replies (1) of 34

Friday January 28, 11:51 am Eastern Time RESEARCH ALERT - Triangle Pharma raised SAN FRANCISCO, Jan 28 (Reuters) - Robertson Stephens said Friday that analyst Michael King raised his rating on Triangle Pharmaceuticals to strong buy from a buy. --increased price target to $28 per share. --said that while Triangle trades below its most direct comparable companies, the stock warrants a premium to its antiviral drug development peer group, based on the number and stage of development of its product candidates. --expects data to be presented on Triangle's most significant commercial compound Coviracil at the upcoming Retrovirus conference in San Francisco to be strong, with a substantial portion of patients below the level of detection. Hmmm. Upgrade move stock up but flat since then. Jack

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next